PubMed HealthSearch

Biomedical subjects

Ching-Yu Cheng

Publications and source records attributed to Ching-Yu Cheng.

4 recordsLinked to original sources

BriGHT: transcriptome-regularized multimodal neuroimaging for brain disorder prediction.

MOTIVATION: Hypergraph-based models for brain disorder prediction mainly adopt imaging-derived hypergraphs as propagation backbones. However, the entanglement of topology construction and feature propagation leaves regional representations weakly constrained by underlying biological organization, making them vulnerable to subject-specific variation and noise, particularly in heterogeneous multimodal settings. RESULTS: We present BriGHT, a Brain transcriptome-reGularized Hypergraph framework for mulTimodal disorder prediction. BriGHT employs a transcriptome-derived structural reference as a soft anchoring prior to regularize neuroimaging ROI embeddings, stabilizing representation geometry while preserving disease-relevant subject-specific variation. BriGHT further incorporates a reliability-aware fusion module to estimate subject-specific modality reliability from prediction confidence, cross-modal consistency, and decision certainty, enabling adaptive integration under heterogeneous modality quality. Experiments on three neuroimaging cohorts (ADNI, ADHD-200, REST-meta-MDD) and four modalities (VBM, fMRI, FDG, AV45) demonstrate that BriGHT consistently outperforms competing graph/hypergraph learning methods across six brain disorder prediction tasks. Perturbation analyses show that BriGHT benefits from the spatial correspondence between transcriptomic modules and imaging ROIs, rather than from arbitrary hypergraph regularization alone. Ablation and meta-analytic interpretability analyses support the contribution of transcriptomic anchoring and adaptive fusion to robust and biologically meaningful brain disorder prediction. AVAILABILITY: The software is publicly available at: https://github.com/Yaolab-fantastic/BriGHT. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Journal Article

Effectiveness of Auricular Acupressure in Improving Sleep Quality and Reducing Insomnia Severity in Middle-Aged and Older Women in Taiwan.

Poor sleep quality impacts cognition, emotions, and immunity. This study evaluated the efficacy of auricular acupressure in improving sleep conditions. Eighty-eight women aged ≥40 years with insomnia were randomly assigned to acupoint, sham, or comparison groups. Magnetic pellets were applied to heart, liver, and shenmen acupoints for the acupoint group and were offset by 1 to 2 cm for the sham group. Participants pressed pellets thrice daily for 1 month. In the acupoint and sham groups, insomnia was reduced and sleep quality improved dramatically in the acupoint group at 4 weeks. Auricular acupressure may improve sleep and support equitable, cultural patient-centered care.

Adult

Efficacy, tolerability, and threshold effect of atropine eye drops for myopia control: A systematic review and dose-response meta-analysis.

Atropine is an emerging therapy for myopia, yet the optimal concentration for prescription remains uncertain. We searched PubMed, Embase, Web of Science, Cochrane Library, World Health Organization International Clinical Trials, and ClinicalTrials.gov registry platforms. We included the randomized clinical trials (RCTs) that compared any dose of atropine against a placebo in myopic children. Among 3566 studies assessed, we identified 33 eligible RCTs involving 6301 children aged 4-18 years, with 10 different concentrations and a mean follow-up time of 19.5&#x202f;&#xb1;&#x202f;12.3 months. A nonlinear relationship was observed between atropine dosage and treatment efficacy (P&#x202f;<&#x202f;0.001). Compared to placebo groups, the mean differences in reducing annual spherical equivalent refraction progression for atropine concentrations of 0.01%, 0.02%, 0.03%, 0.04%, and 0.05% were 0.21 diopters (D) (95% CI, 0.13-0.28), 0.35 D (95% CI, 0.23-0.46), 0.42 D (95% CI, 0.28-0.56), 0.45 D (95% CI, 0.30-0.60), and 0.46 D (95% CI, 0.32-0.61) respectively For higher concentrations, the estimates were 0.49 D (95% CI, 0.34-0.63) for 0.1% and 0.99 D (95% CI, 0.66-1.31) for 1%, although these were based on fewer and smaller trials. Higher doses of atropine were associated with decreased amplitude of accommodation (P&#x202f;=&#x202f;0.02), increased pupil diameters (P&#x202f;=&#x202f;0.01) and a higher frequency of photophobia (P&#x202f;=&#x202f;0.02). Our findings suggest that the increase in treatment efficacy with higher concentrations may plateau beyond a certain range, and that the current practice of increasing atropine concentrations for children who show inadequate responses to lower doses should be confined to a specific concentration range. This analysis is limited by the number, design heterogeneity, and sample sizes of available trials for higher concentrations, and by the frequent lack of pre-intervention refractive history in included studies. Therefore, estimates-particularly for doses exceeding 0.1%-should be interpreted with caution.

Humans